{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:13:48Z","timestamp":1780586028900,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01777-z","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:26:04Z","timestamp":1778639164000},"page":"3189-3200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04183335","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04202679","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mendes-Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy H.","family":"Praestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simmi","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"7","key":"1777_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ced.14722","volume":"46","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal P, Choi J, Sutaria N, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277\u201384.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1777_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/00015555-2774","volume":"98","author":"C Zeidler","year":"2018","unstructured":"Zeidler C, Tsianakas A, Pereira M, St\u00e4nder H, Yosipovitch G, St\u00e4nder S. Chronic prurigo of nodular type: a review. Acta Derm Venereol. 2018;98(2):173\u20139.","journal-title":"Acta Derm Venereol"},{"key":"1777_CR3","doi-asserted-by":"crossref","unstructured":"Pereira MP, Hoffman V, Weisshaar E, et al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol. 2020;34(10):2373\u201383.","DOI":"10.1111\/jdv.16309"},{"issue":"8","key":"1777_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00403-020-02148-0","volume":"313","author":"SR Janmohamed","year":"2021","unstructured":"Janmohamed SR, Gwillim EC, Yousaf M, Patel KR, Silverberg JI. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis. Arch Dermatol Res. 2021;313(8):669\u201377.","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"1777_CR5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase\u00a03 trials. Nat Med. 2023;29(5):1180\u201390.","journal-title":"Nat Med"},{"issue":"4","key":"1777_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jdv.17870","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder S, Zeidler C, Pereira M, et al. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022;36(4):573\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1777_CR7","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3701","volume":"101","author":"C Zeidler","year":"2021","unstructured":"Zeidler C, Pereira MP, Augustin M, Spellman M, St\u00e4nder S. Investigator\u2019s global assessment of chronic prurigo: a new instrument for use in clinical trials. Acta Derm Venereol. 2021;101(2):adv00401.","journal-title":"Acta Derm Venereol"},{"key":"1777_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jdin.2024.03.025","volume":"16","author":"G Yosipovitch","year":"2024","unstructured":"Yosipovitch G, Kim BS, Kwatra SG, et al. Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: pooled results from two phase\u00a03 trials (LIBERTY-PN PRIME and PRIME2). JAAD Int. 2024;16:163\u201374.","journal-title":"JAAD Int"},{"issue":"7","key":"1777_CR9","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/jdv.19800","volume":"38","author":"S St\u00e4nder","year":"2024","unstructured":"St\u00e4nder S, Kim BS, Guillemin I, et al. Estimating meaningful change thresholds for Skin-Pain Numeric Rating Scale, Sleep-Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2024;38(7):1401\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1777_CR10","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1111\/jdv.19961","volume":"38","author":"C Zeidler","year":"2024","unstructured":"Zeidler C, St\u00e4nder S, Rhoten S, et al. Validation of a scoring algorithm for the clinician-reported outcome tool \u201cPrurigo Activity and Severity (PAS)\u201d based on clinical studies of dupilumab in adults with prurigo nodularis. J Eur Acad Dermatol Venereol. 2024;38(10):1954\u201364.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1777_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1600-0560.2009.01484.x","volume":"37","author":"N Weigelt","year":"2010","unstructured":"Weigelt N, Metze D, St\u00e4nder S. Prurigo nodularis: systematic analysis of 58\u00a0histological criteria in 136 patients. J Cutan Pathol. 2010;37(5):578\u201386.","journal-title":"J Cutan Pathol"},{"issue":"10","key":"1777_CR12","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1111\/jdv.20148","volume":"38","author":"MP Pereira","year":"2024","unstructured":"Pereira MP, Zeidler C, Szymczak H, et al. Acceptability and perceived benefits of validated pruritus assessment instruments in the dermatological office and clinic: the perspectives of patients and physicians. J Eur Acad Dermatol Venereol. 2024;38(10):1973\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1777_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MKA Basra","year":"2015","unstructured":"Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27\u201333.","journal-title":"Dermatology"},{"issue":"10","key":"1777_CR14","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/jdv.20099","volume":"38","author":"SG Kwatra","year":"2024","unstructured":"Kwatra SG, Yosipovitch G, St\u00e4nder S, et al. Responder analysis using clinically meaningful thresholds: post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2024;38(10):1965\u201372.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"1777_CR15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2340\/00015555-2433","volume":"96","author":"A Reich","year":"2016","unstructured":"Reich A, Riepe C, Anastasiadou Z, et al. Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol. 2016;96(7):978\u201380.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1777_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jamadermatol.2024.1634","volume":"160","author":"SG Kwatra","year":"2024","unstructured":"Kwatra SG, Yosipovitch G, Kim B, et al. Worst Itch Numeric Rating Scale for prurigo nodularis: a secondary analysis of two randomized clinical trials. JAMA Dermatol. 2024;160(8):813\u201321.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1777_CR17","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamadermatol.2020.3071","volume":"156","author":"M Kimel","year":"2020","unstructured":"Kimel M, Zeidler C, Kwon P, Revicki D, St\u00e4nder S. Validation of the psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: a secondary analysis of a randomized clinical trial. JAMA Dermatol. 2020;156(12):1354\u20138.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"1777_CR18","doi-asserted-by":"publisher","first-page":"e892","DOI":"10.1111\/jdv.19980","volume":"38","author":"A Chiricozzi","year":"2024","unstructured":"Chiricozzi A, Gori N, Ippoliti E, et al. Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: a real-world retrospective study. J Eur Acad Dermatol Venereol. 2024;38(10):e892\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1777_CR19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/jcm13030878","volume":"13","author":"C Paganini","year":"2024","unstructured":"Paganini C, Talamonti M, Maffei V, Di Raimondo C, Bianchi L, Galluzzo M. Dupilumab for treatment of prurigo nodularis: real-life effectiveness for up to 84\u00a0weeks. J Clin Med. 2024;13(3):878.","journal-title":"J Clin Med"},{"key":"1777_CR20","doi-asserted-by":"crossref","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402.","DOI":"10.2340\/00015555-3751"},{"key":"1777_CR21","doi-asserted-by":"crossref","unstructured":"Yeung J, Gooderham MJ, Hong HC-H, et al. Treat-to-target in the management of moderate-to-severe atopic dermatitis in adults: a Canadian perspective. J Am Acad Dermatol. 2023;89(2):372\u20135.","DOI":"10.1016\/j.jaad.2023.01.053"},{"issue":"1","key":"1777_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smollen","year":"2016","unstructured":"Smollen JS, Breedvelt FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1777_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.04411.x","volume":"Suppl 2","author":"U Mrowietz","year":"2012","unstructured":"Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol. 2012;Suppl 2:12\u201320.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01777-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01777-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:54:09Z","timestamp":1780584849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01777-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1777"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01777-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sonja St\u00e4nder has served as a consultant for AbbVie, Almirall, Beiersdorf, Clexio, Escient, Galderma, Gr\u00fcnenthal, Incyte, Integrity CE, Kiniksa, Klinge Pharma, Lilly, P.G. Unna Academy, Pfizer, Sanofi, Touch IME, Vifor, WebMD; an advisory board member for AbbVie, Almirall, Galderma, Lilly, Pfizer, Sanofi, Vifor; a speaker for AbbVie, BMS, FomF, Galderma, LEO Pharma, L'Or\u00e9al, MEDahead, Moroscience, Novartis, P.G. Unna Academy, Pfizer, Sanofi, UCB, Vifor; received research grants from Almirall, Beiersdorf, Galderma, and Sanofi and is an editorial board member of\n                      Dermatology and Therapy\n                      . Sonja St\u00e4nder was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Gil Yosipovitch has served as an advisory board member for AbbVie, Almirall, Amgen, Arcutis, Celldex, Eli Lilly, Escient Health, Galderma, GSK, LEO Pharma, Merck, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, and Vifor; received grants\/research funding from Eli Lilly, Escient, Galderma, Kiniksa, LEO Pharma, Novartis, Pfizer, Sanofi, Celldex, Regeneron Pharmaceuticals Inc., and Sanofi; served as an investigator for Galderma, Regeneron Pharmaceuticals Inc., and Sanofi and is an editorial board member of\n                      Dermatology and Therapy\n                      . Gil Yosipovitch was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Shawn G. Kwatra has served as an advisory board member\/consultant for AbbVie, Arcutis Biotherapeutics, ASLAN Pharmaceuticals, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte, Johnson & Johnson, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi; and an investigator for Galderma, Incyte, Pfizer, and Sanofi. P. Mendes-Bastos has served as a principal investigator for AbbVie, Janssen-Cilag, Novartis, Pfizer, and Sanofi; and a speaker\/consultant for AbbVie, Almirall, Alumis, Apogee, CS Labs, Eli Lilly, Evelo Biosciences, GlaxoSmithKline, Johnson & Johnson Innovative Medicine, LEO Pharma, L\u2019Or\u00e9al, Novartis, Organon, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., Sanofi, Takeda, and Viatris. Tsen-Fang Tsai has received consultant honoraria from AbbVie; investigator fees (paid to institution) from AbbVie, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen-Cilag, Novartis, Pfizer, PharmaEssentia, and Sanofi; advisory board member honoraria from Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen-Cilag, and Pfizer; and speaker honoraria from Boehringer Ingelheim; and has served as chair of the Taiwanese Association for Psoriasis and Skin Immunology and as an editorial board member of\n                      Dermatology and Therapy\n                      . Tsen-Fang Tsai was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Saeko Nakajima has received research funding from Maruho and Toyota; has served as a consultant for Torii Pharmaceutical; and has been a speaker for AbbVie, Boehringer Ingelheim, Eli Lilly, Maruho, Meiji Seika Pharma, Pfizer, Sanofi, and Torii Pharmaceutical. Amy H. Praestgaard and Simmi Wiggins are employees at Sanofi and may hold stock and\/or stock options in the company. Joseph Zahn is an employee and shareholder of Regeneron Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements. The local institutional review board\/ethics committee at each study center oversaw trial conduct and documentation. Patients provided written informed consent before participating in the trial. Consent for publication was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}